Search Result

Results for "

PBMCs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) ADC Cytotoxin (1) Amylases (1) Antibiotic (6) Apoptosis (15) Bacterial (6) BCRP (1) Biochemical Assay Reagents (2) Btk (1) Calcium Channel (1) Caspase (2) Cathepsin (1) CCR (5) CD20 (1) CD28 (1) CD3 (2) CD38 (1) CD6 (1) CDK (2) CRAC Channel (1) CXCR (3) Dengue Virus (3) Deubiquitinase (1) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (3) Endogenous Metabolite (5) Epigenetic Reader Domain (3) Epoxide Hydrolase (1) Eukaryotic Initiation Factor (eIF) (2) Fatty Acid Synthase (FASN) (1) FLAP (1) Flavivirus (3) Glucocorticoid Receptor (2) Glutathione S-transferase (1) Glycosidase (1) HBV (1) Heme Oxygenase (HO) (1) Histone Demethylase (1) HIV (34) HIV Integrase (3) HIV Protease (4) IFNAR (8) IKK (5) Interleukin Related (16) IRAK (4) Isotope-Labeled Compounds (2) Itk (1) JAK (6) Kinesin (1) LAG-3 (1) Ligands for E3 Ligase (1) Liposome (1) LRRK2 (2) MALT1 (1) MAP4K (5) Mineralocorticoid Receptor (1) MMP (3) Monocarboxylate Transporter (1) MyD88 (2) NF-κB (3) NOD-like Receptor (NLR) (6) Nucleoside Antimetabolite/Analog (1) p38 MAPK (2) Parasite (1) PD-1/PD-L1 (7) Phosphodiesterase (PDE) (6) Piezo Channel (1) PIKfyve (2) PROTACs (4) Protease Activated Receptor (PAR) (2) Proteasome (3) PTEN (1) PTHR (1) Pyroptosis (1) RANKL/RANK (1) Reverse Transcriptase (6) RIP kinase (1) ROR (3) SARS-CoV (5) Ser/Thr Protease (2) STAT (1) STING (4) TGF-beta/Smad (1) Tim3 (2) TNF Receptor (13) Toll-like Receptor (TLR) (26) Virus Protease (3) VISTA (1)
By Research Areas:	Cancer (55) Cardiovascular Disease (2) Endocrinology (6) Infection (51) Inflammation/Immunology (110) Metabolic Disease (8) Neurological Disease (11)
Click Chemistry:	Azide (2) Alkynes (1)
Oligonucleotides:	CpG ODNs (17) Phospholipids (1)

189

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19775

GNE-6468	ROR	Inflammation/Immunology
GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC₅₀ value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC₅₀ of 30 nM for IL-17 PBMC .

HY-114592

M199	Toll-like Receptor (TLR) Interleukin Related TNF Receptor	Inflammation/Immunology
M199 is a potent TLR3/TLR9 signaling inhibitor. M199 induces secretion of IL-6, IL-8 and TNFα in human PBMCs. M199 is used as a selective inducer of the immune response .

HY-21496

4-(Bromomethyl)benzoic acid 4-Carboxybenzyl bromide	Parasite	Infection
4-(Bromomethyl)benzoic acid (4-Carboxybenzyl bromide) is an antiparasitic agent with low activity against Leishmania amazonensis and Trypanosoma cruzi. 4-(Bromomethyl)benzoic acid has certain cytotoxicity to PBMCs, with an IC₅₀ of 88.8 μM .

HY-N7696

Physalin F	Apoptosis	Inflammation/Immunology
Physalin F is a secosteroid with potent anti-inflammatory and immunomodulatory activities. Physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by Human T-lymphotropic virus type 1 (HTLV-1) infection .

HY-N12988

Dihydrobonducellin	Interleukin Related	Inflammation/Immunology
Dihydrobonducellin (compound 5) is a an immunomodulator. Dihydrobonducellin inhibits cell groth and the production of IL-2 and IFN-γ in PBMC cells .

HY-160231

ssRNA42 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ssRNA42 (sodium) is a 20-mer phosphothioate protected single-stranded RNA oligonucleotide. ssRNA42 (sodium) derives from ssRNA40 by replacement of all G nucleotides with adenosine. ssRNA42 activated human PBMCs to secrete IFN-α, TNF-a, IL- 12p40, and IL-6, but ssRNA42 failed to stimulated murine pDCs and PBMCs.

HY-120245

GSK-340	Epigenetic Reader Domain	Inflammation/Immunology
GSK-340 is a BET inhibitor with high affinity and significant selectivity for BD2 from BRD4 with a pIC50 of 7.2. GSK-340 inhibits MCP-1 release in Lipopolysaccharide (HY-D1056) treated PBMCs and whole blood with the pIC50 of 7.4 and 6.0, respectively. GSK-340 has immunomodulatory activity .

HY-162544

PROTAC HPK1 Degrader-2	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-2 (compound 3) is a PROTAC degrader of HPK1, with the DC₅₀ of 23 nM in human PBMC. PROTAC HPK1 Degrader-2 plays an important role in cancer research .

HY-168041

LRRK2-IN-15	LRRK2 BCRP	Neurological Disease
LRRK2-IN-15 is an LRRK2 inhibitor. The IC₅₀ value for PBMC cells is 5 nM, and the IC₅₀ value for BCRP is 1.5 μM. LRRK2-IN-15 can be used for research on Parkinson's disease .

HY-148643

STING modulator-5	STING	Inflammation/Immunology
STING modulator-5 (compound 38) is a STING modulator with a pIC₅₀ value of 9.5. STING modulator-5 antagonizes peripheral blood mononuclear cells (PBMC) with a pIC₅₀ value of 8.1. STING modulator-5 is a antagonist of THP-1 cells, it can be used for immunological disease research .

HY-156329

sEH/FLAP-IN-1	Epoxide Hydrolase FLAP	Inflammation/Immunology
sEH/FLAP-IN-1 (Compound 46A) is a sEH/FLAP inhibitor. sEH/FLAP-IN-1 inhibits 5-LOX product formation in SACM-stimulated PBMCs (EC₅₀: 11 nM). sEH/FLAP-IN-1 inhibit sEH (EC₅₀: 18 nM) and thromboxane production. sEH/FLAP-IN-1 can be used for research of inflammatory diseases .

HY-146308

HIV-1 inhibitor-26	HIV	Infection
HIV-1 inhibitor-26 (compound 9a) is a potent HIV-1 reverse transcriptase (RT) inhibitor with an IC₅₀ value of 1.4 μM. HIV-1 inhibitor-26 has low cytotoxicity with a CC₅₀ of 1486 μM in PBMCs. HIV-1 inhibitor-26 can be used for researching AIDS .

HY-103697

Gardiquimod	Toll-like Receptor (TLR)	Cancer
Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.

HY-150749

ODN D-SL03	IFNAR	Inflammation/Immunology Cancer
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-150749A

ODN D-SL03 sodium	IFNAR	Cancer
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-153050

JAK-IN-24	JAK	Inflammation/Immunology Cancer
JAK-IN-24 is a JAK inhibitor, with IC₅₀s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC₅₀ of 86.171 nM . JAK-IN-24 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103697B

Gardiquimod hydrochloride	HIV Toll-like Receptor (TLR)	Infection Cancer
Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM .

HY-103697A

Gardiquimod diTFA	Toll-like Receptor (TLR)	Cancer
Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-147506

NOD2 antagonist 1	NOD-like Receptor (NLR)	Inflammation/Immunology
NOD2 antagonist 1 (compound 32) is a potent and selective NOD2 antagonist with an IC₅₀ of 5.23 μM. NOD2 antagonist 1 inhibits Muramyl dipeptide (MDP)-induced IL-8 secretion in THP-1 cells and inhibits MDP-induced IL-6, IL-10, TNF-α release in PBMCs .

HY-100546

GSK-LSD1	Histone Demethylase	Infection Metabolic Disease Cancer
GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .

HY-111964

Lenacapavir 10+ Cited Publications GS-6207	HIV	Infection
Lenacapavir (GS-6207) is a HIV-1 capsid inhibitor. Lenacapavir shows anti-HIV activity with an EC₅₀ of 100 pM in MT-4 cells. Lenacapavir displays a mean EC₅₀ of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs) . Lenacapavir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P4984

Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78)	Biochemical Assay Reagents	Inflammation/Immunology Cancer
Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is a T cell proliferation activator. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) promotes the in vitro proliferation of human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) can be used in research on inflammatory and immunity, as well as cancer .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-153900

TLR8 agonist 6	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 6 (Compound A) is a TLR8 agonist, with an EC₅₀ of 0.052 μM. TLR8 agonist 6 induces IL-12p40 production in human PBMC (EC₅₀: 0.031 μM). TLR8 agonist 6 can be used in the research of virus resistance, infection resistance, autoimmunity, tumor, etc .

HY-149356

PD-1/PD-L1-IN-31	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC₅₀=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .

HY-144987

RBN013209 1 Publications Verification	CD38 LAG-3 Tim3 PD-1/PD-L1	Inflammation/Immunology Cancer
RBN013209 is an orally active small molecule inhibitor of CD38 with an IC₅₀ of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD ⁺ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors .

HY-147832

EIF2α activator 2	Eukaryotic Initiation Factor (eIF)	Cancer
EIF2α activator 2 (Compound 1) is an activator of eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation. EIF2α activator 2 exhibits high potency in SRB cell proliferation assays (IC₅₀=0.46 μM). EIF2α activator 2 exhibits antiproliferative activity againist K562 and PBMC cells with IC₅₀s of 4.79 and 10.52 μM, respectively .

HY-143305

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer .

HY-147831

EIF2α activator 1	Eukaryotic Initiation Factor (eIF)	Cancer
EIF2α activator 1 (Compound 40) is an activator of eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation. EIF2α activator 1 increases the expression level of eIF2α downstream proteins, ATF and CHOP. EIF2α activator 1 exhibits antiproliferative activity againist K562 and PBMC cells with IC₅₀s of 4.00 and 19.3 μM, respectively .

HY-106850

3′-Azido-2′,3′-dideoxyuridine AzdU; AzddU; CS-87	HIV	Infection
3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-162579

TLR7 agonist 22	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 22 (Compound 11a) emerges as a selective TLR7 agonist with an IC₅₀ value of 25.86 μM. TLR7 agonist 22 inhibits the cellular HBsAg secretion and effectively activates TLR7, thereby inducing the secretion of TLR7-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents .

HY-153673

PROTAC IRAK4 degrader-8	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC IRAK4 degrader (IC₅₀: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC₅₀: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC₅₀s of 246 nM and 2.2 nM respectively .

HY-135382

PROTAC IRAK4 degrader-2	PROTACs IRAK	Inflammation/Immunology Cancer
PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC₅₀ in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC₅₀ of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .

HY-151871

ICeD-2	Dipeptidyl Peptidase HIV	Infection
ICeD-2 is a inducer of cell death, can induce HIV-1 infected cell kill. ICeD-2-mediated HIV-1 infected cell kill is dependent on HIV-1 protease activity. ICeD-2 potently blocks hydrolysis of Gly-Pro-AMC by dipeptidyl peptidase DPP8 and DPP9. ICeD-2 shows strong stabilization of DPP9 in PBMCs .

HY-144649

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs .

HY-156438

NT-0796	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease
NT-0796 is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. NT-0796 inhibits IL-1β release in human PBMC cells with an IC₅₀ value of 0.32 nM. NT-0796 is an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. NT-0796 is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .

HY-P990090

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

HY-109014

Tenofovir exalidex CMX-157	HIV HBV Nucleoside Antimetabolite/Analog	Infection
Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC₅₀s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV .

HY-14644A

Apilimod mesylate 25+ Cited Publications STA 5326 mesylate; LAM-002A; AIT-101 mesylate	Interleukin Related PIKfyve	Inflammation/Immunology Cancer
Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC₅₀s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively . Apilimod is a potent and highly selective PIKfyve inhibitor.

HY-14644

Apilimod 25+ Cited Publications STA 5326; LAM-002A free base; AIT-101	Interleukin Related PIKfyve	Inflammation/Immunology Cancer
Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC₅₀s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively . Apilimod is a potent and highly selective PIKfyve inhibitor.

HY-113953

Z-Asp-CH2-DCB	Caspase Apoptosis	Inflammation/Immunology
Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development .

HY-17427

Emtricitabine 5 Publications Verification BW1592	HIV Reverse Transcriptase Endogenous Metabolite	Infection
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-150701

INCB13739	Glucocorticoid Receptor Mineralocorticoid Receptor 11β-HSD	Metabolic Disease
INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC₅₀ values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research .

HY-134820

MLT-943	MALT1	Inflammation/Immunology
MLT-943 is a potent, selective and orally active MALT1 protease inhibitor. MLT-943 inhibits stimulated-IL-2 secretion in PBMC or in whole blood with a similar IC₅₀ across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood). MLT-943 has anti-inflammatory activities and can be used for FcgR-mediated inflammation research .

HY-170684

DHX9-IN-19	DNA/RNA Synthesis	Cancer
DHX9-IN-19 (compound 3) is an orally active and potent inhibitor of DHX9. DHX9-IN-19 plays an important role in cancer research .

HY-168219

JMS-175-2	Deubiquitinase	Inflammation/Immunology
JMS-175-2 is a potent agonist of BRCC36 isopeptidase complex (BRISC), with the IC₅₀ of 3.8 μM. JMS-175-2 plays an important role in Type I interferon-mediated diseases .

HY-159884

MG-T-19	Tim3 TNF Receptor IFNAR	Cancer
MG-T-19 is an effective TIM-3 inhibitor that can suppress the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9. MG-T-19 can increase the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors, and enhance the ability of PBMCs to inhibit the proliferation of Kasumi-1 cells (an acute myelogenous leukemia cell line) .

HY-132248

C5 Lenalidomide Lenalidomide 5'-amine	TNF Receptor	Inflammation/Immunology
C5 Lenalidomide (Lenalidomide 5'-amine) is a thalidomide analog and is a potent inhibitor of TNF-alpha production (IC₅₀=100 μM in LPS stimulated human PBMC) .

HY-17427R

Emtricitabine (Standard) BW1592 (Standard)	HIV Reverse Transcriptase Endogenous Metabolite	Infection
Emtricitabine (Standard) is the analytical standard of Emtricitabine. This product is intended for research and analytical applications. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

Cat. No.	Product Name	Type

HY-142989

1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine

Drug Delivery

1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that is a constituent of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs) in a molar ratio of 1.5:1.5:1:1 with 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol, and l-α-phosphatidylserine. PERLs can reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and reduce HIV-1 particle secretion from HIV-1 infected PBMCs .

Cat. No.	Product Name	Target	Research Area

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P4984

Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78)	Biochemical Assay Reagents	Inflammation/Immunology Cancer
Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is a T cell proliferation activator. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) promotes the in vitro proliferation of human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) can be used in research on inflammatory and immunity, as well as cancer .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P4684

Osteostatin PTHrP (107–111)	PTHR	Inflammation/Immunology
Osteostatin, a fragment of parathyroid hormone-related protein (PTHrP) 107-111, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis, inhibits collagen-induced arthritis and inhibits osteoclastic bone resorption directly. Osteostatin can be used for inflammation and immunology research .

HY-P2313

Human β-defensin-2 HβD-2	Antibiotic Bacterial	Infection
Human β-defensin-2 (HβD-2) is a small cysteine-rich cationic skin-antimicrobial peptide (SAP) produced by a number of epithelial cells.Human β-defensin-2 has antimicrobial activity against gram-negative bacteria and Candida, but not gram-positive Staphylococcus aureus . Human β-defensin-2 can be used for the study of colitis .

Cat. No.	Product Name

HY-K0304

Human CD3⁺ T Cells Negative Selection Kit
MCE Human CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from human peripheral blood mononuclear cells (PBMC).

HY-K0351

Human CD8⁺ T Cells Negative Selection Kit
MCE Human CD8⁺ T Cells Negative Selection Kit is designed to isolate CD8⁺ T cells from human peripheral blood mononuclear cells (PBMCs).

HY-K0305

Human CD34⁺ Cells Negative Selection Kit
MCE Human CD34⁺ Cells Negative Selection Kit is designed for the isolation of CD34⁺ cells from human cord blood mononuclear cells (CBMC) or human peripheral blood mononuclear cells (PBMC).

HY-K0352

Human CD4⁺ T Cells Negative Selection Kit
MCE Human CD4⁺ T Cells Negative Selection Kit is designed to isolate CD4⁺ T cells from human peripheral blood mononuclear cells (PBMCs).

Cat. No.	Product Name	Target	Research Area

HY-P990090

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99327

Tregalizumab BT-061	Inhibitory Antibodies	Inflammation/Immunology
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .

HY-P99257

Bleselumab ASKP 1240	TNF Receptor	Inflammation/Immunology
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (K_d: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .

HY-P9958A

Denosumab (anti-TNFSF11) 1 Publications Verification	RANKL/RANK Apoptosis NF-κB	Neurological Disease Endocrinology Cancer
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

HY-P99670

Iscalimab CFZ-533; OM11-62MF	TNF Receptor	Metabolic Disease Inflammation/Immunology
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (K_D: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99168

Anifrolumab 2 Publications Verification	IFNAR	Inflammation/Immunology
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99775

Placulumab ART621; CEP-37247; PN0621	TNF Receptor	Inflammation/Immunology
Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .

HY-P99252

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .

HY-108813

Belatacept BMS 224818; LEA 29Y	Inhibitory Antibodies	Inflammation/Immunology
Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation .

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Inflammation/Immunology Cancer
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 ⁺ non-Hodgkin lymphomas .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7696

Physalin F	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Physalis angulata L. Solanaceae Plants Inflammation/Immunology Disease Research Fields	Apoptosis
Physalin F is a secosteroid with potent anti-inflammatory and immunomodulatory activities. Physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by Human T-lymphotropic virus type 1 (HTLV-1) infection .

HY-17427

Emtricitabine 5 Publications Verification BW1592	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	HIV Reverse Transcriptase Endogenous Metabolite
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-17427R

Emtricitabine (Standard) BW1592 (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	HIV Reverse Transcriptase Endogenous Metabolite
Emtricitabine (Standard) is the analytical standard of Emtricitabine. This product is intended for research and analytical applications. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-N1196

Suberosin	Structural Classification Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Plants Pluchea indica (L.) Less. Inflammation/Immunology Disease Research Fields	NF-κB
Suberosin, isolated from Plumbago zeylanica, exhibits anti-inflammatory and anticoagulant activity. Suberosin suppresses PHA-induced PBMC proliferation and arrested cell cycle progression from the G1 transition to the S phase through the modulation of the transcription factors NF-AT and NF-κB .

HY-N2116

Ginkgolic acid C17:1	Structural Classification Monophenols Ginkgoaceae Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Plants Ginkgo biloba Disease Research Fields Cancer	PTEN Fatty Acid Synthase (FASN) STAT Apoptosis SARS-CoV
Ginkgolic acid C17:1 is a fatty acid synthase (FAS) inhibitor with an IC₅₀ of 10.5 µM. Ginkgolic acid C17:1 shows anti-tumor activity by inhibiting the phosphorylation of STAT3 and inducing apoptosis. Ginkgolic acid C17:1 can block the interaction between S-RBD and ACE2, and has anti-SARS-CoV-2-S pseudovirus activity. Ginkgolic acid C17:1 inhibits the biofilm formation of enterohemorrhagic Escherichia coli and Staphylococcus aureus .

HY-N12988

Dihydrobonducellin	Structural Classification Monophenols Source classification Phenols Agavaceae Plants Agave sisalana Perr. ex Engelm.	Interleukin Related
Dihydrobonducellin (compound 5) is a an immunomodulator. Dihydrobonducellin inhibits cell groth and the production of IL-2 and IFN-γ in PBMC cells .

HY-N13236

Echinacea Purpurea Extract	Infection Classification of Application Fields Source classification Metabolic Disease Plants Compositae Disease Research Fields	Others
Echinacea Purpurea Extract is an echinacea extract, and its ingredients include: Polyphenols. Echinacea Purpurea Extract is a potential anti-inflammatory agent that can inhibit LPS-induced inflammatory responses in yak peripheral blood mononuclear cells (PBMCs). .

HY-N15408

Terminaline	Structural Classification Natural Products Sarcococca saligna (D. Don) Mull.-Arg. Buxaceae Source classification Plants	Interleukin Related
Terminaline is a compound that can be isolated from Sarcococca saligna. Terminaline has immunosuppressive activity and can inhibit the proliferation of T cells and the production of IL-2. In vivo, Terminaline can reduce CCl₄-induced liver injury and has a good hepatoprotective effect .

Cat. No.	Product Name	Chemical Structure

HY-17427S

Emtricitabine-15N,d2
Emtricitabine- ¹⁵N,d₂ is a ¹⁵N-labeled and deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-12085S

Apremilast-d5
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].

HY-17427S4

Emtricitabine-d2
Emtricitabine-d₂ (BW1592-d₂) is deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-17427S2

Emtricitabine-13C,15N2
Emtricitabine- ¹³C, ¹⁵N₂ (BW1592- ¹³C, ¹⁵N₂) is a ¹³C- and ¹⁵N-labeled Emtricitabine (HY-17427). Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

Cat. No.	Product Name		Classification

HY-153050

JAK-IN-24		Alkynes
JAK-IN-24 is a JAK inhibitor, with IC₅₀s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC₅₀ of 86.171 nM . JAK-IN-24 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106850

3′-Azido-2′,3′-dideoxyuridine AzdU; AzddU; CS-87		Azide
3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-159100

PVP-037		Azide
PVP-037 is a potent TLR7 and TLR8 agonist adjuvant. PVP-037 shows broad innate immune activation and enhances vaccine immune responses .

Cat. No.	Product Name		Classification

HY-150749A

ODN D-SL03 sodium		CpG ODNs
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-142989

1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine		Phospholipids
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that is a constituent of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs) in a molar ratio of 1.5:1.5:1:1 with 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol, and l-α-phosphatidylserine. PERLs can reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and reduce HIV-1 particle secretion from HIV-1 infected PBMCs .

HY-150738C

ODN 2088 sodium		CpG ODNs
ODN 2088 sodium is a potent TLR3, TLR7 and TLR9 inhibitor. ODN 2088 sodium shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .

HY-150738

ODN 2088		CpG ODNs
ODN 2088 is a potent TLR3, TLR7 and TLR9 inhibitor. ODN 2088 shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .

HY-160231

ssRNA42 sodium		CpG ODNs
ssRNA42 (sodium) is a 20-mer phosphothioate protected single-stranded RNA oligonucleotide. ssRNA42 (sodium) derives from ssRNA40 by replacement of all G nucleotides with adenosine. ssRNA42 activated human PBMCs to secrete IFN-α, TNF-a, IL- 12p40, and IL-6, but ssRNA42 failed to stimulated murine pDCs and PBMCs.

HY-150749

ODN D-SL03		CpG ODNs
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-150739

ODN 21158		CpG ODNs
ODN 21158 is a potent G-modified TLR3 and TLR9 inhibitor. ODN 21158 shows no cytotoxic. ODN 21158 inhibits IFN-α secretion in a dose dependent manner .

HY-150739A

ODN 21158 sodium		CpG ODNs
ODN 21158 sodium is a potent G-modified TLR3 and TLR9 inhibitor. ODN 21158 sodium inhibits IFN-α secretion in a dose dependent manner .

HY-150740A

ODN 21595 sodium		CpG ODNs
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740

ODN 21595		CpG ODNs
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150741C

ODN 2216 sodium 1 Publications Verification		CpG ODNs
ODN 2216 sodium is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN 2216 sodium induces high amounts of IFN-α and IFN-β. ODN 2216 sodium induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 sodium stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 sodium can activate NK cells and promote IFN-γ production of TCR-triggered CD4 ⁺ T cells .

HY-150741

ODN 2216		CpG ODNs
ODN 2216 is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN 2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4 ⁺ T cells .

HY-150742A

ODN 2336 sodium		CpG ODNs
ODN 2336 sodium is a A-Class CpG ODN (oligodeoxynucleotides), is a potent TLR9 agonist. ODN 2336 sodium induces the production of IFN-α. ODN 2336 sodium up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 sodium can be used as adjuvant of vaccines .

HY-150742

ODN 2336		CpG ODNs
ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent TLR9 agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines .

HY-150745

ODN 24987		CpG ODNs
ODN 24987 is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .

HY-150745A

ODN 24987 sodium		CpG ODNs
ODN 24987 sodium is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 sodium can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .

HY-150744A

ODN 24888 sodium		CpG ODNs
ODN 24888 sodium is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 sodium impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 sodium involves in immune and inflammatory responses, can be used as a vaccine adjuvant .

HY-150744

ODN 24888		CpG ODNs
ODN 24888 is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 involves in immune and inflammatory responses, can be used as a vaccine adjuvant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks